Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Emoviar Pharmacon GmbH currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to a distinct examiner working within a distinct art unit. The concentration of the portfolio suggests a highly focused prosecution effort at this stage. By maintaining a limited number of filings, the company can dedicate more resources to the specific technical requirements of the Biotechnology & Pharmaceuticals sector.
The busiest examiner for the company is CHARANJIT AULAKH, who is responsible for 1 pending office action. Because the busiest examiner pending count matches the total pending office actions, the firm's current workload is entirely centralized under a specific individual's review. This consolidation allows for a tailored response strategy that addresses the particular examination style of the assigned official. The lack of fragmentation across different art units or examiners simplifies the administrative oversight required for the company's intellectual property development. This streamlined approach is particularly beneficial in the complex Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18606095 | SUSTAINED RELEASE DOSAGE FORMS FOR LOW SOLUBILITY COMPOUNDS AND METHODS FOR PREPARING OF THESE SUSTAINED RELEASE DOSAGE FORMS | AULAKH, CHARANJIT | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18606095 | SUSTAINED RELEASE DOSAGE FORMS FOR LOW SOLUBILITY COMPOUNDS AND METHODS FOR PREPARING OF THESE SUSTAINED RELEASE DOSAGE FORMS | AULAKH, CHARANJIT | 1621 | §102§103§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial